DAFTAR PUSTAKA

Abate, M., Vos, E., Gonen, M., Janjigian, Y. Y., Schattner, M., Laszkowska, M., Tang, L., Maron, S. B., Coit, D. G., Vardhana, S., Vanderbilt, C., & Strong, V. E. (2022). A Novel Microbiome Signature in Gastric Cancer: A Two Independent Cohort Retrospective Analysis. *Annals of Surgery*, *276*(4), 605–615. https://doi.org/10.1097/SLA.0000000000005587

Abdullah, M., Greenfield, L. K., Bronte-Tinkew, D., Capurro, M. I., Rizzuti, D., & Jones, N. L. (2019). VacA promotes CagA accumulation in gastric epithelial cells during Helicobacter pylori infection. *Scientific Reports*, *9*(1), 38. https://doi.org/10.1038/s41598-018-37095-4

Ağagündüz, D., Cocozza, E., Cemali, Ö., Bayazıt, A. D., Nanì, M. F., Cerqua, I., Morgillo, F., Saygılı, S. K., Berni Canani, R., & Amero, P. (2023). Understanding the role of the gut microbiome in gastrointestinal cancer: A review. *Frontiers in Pharmacology*, *14*, 1130562.

Ai, B., Mei, Y., Liang, D., Wang, T., Cai, H., & Yu, D. (2023). Uncovering the special microbiota associated with occurrence and progression of gastric cancer by using RNA-sequencing. *Scientific Reports*, *13*(1), 5722. https://doi.org/10.1038/s41598-023-32809-9

Alfarouk, K. O., Bashir, A. H., Aljarbou, A. N., Ramadan, A. M., Muddathir, A. K., AlHoufie, S. T., Hifny, A., Elhassan, G. O., Ibrahim, M. E., & Alqahtani, S. S. (2019). The possible role of Helicobacter pylori in gastric cancer and its management. *Frontiers in Oncology*, *9*, 75.

Alipour, M. (2021). Molecular Mechanism of Helicobacter pylori-Induced Gastric Cancer. *Journal of Gastrointestinal Cancer*, *52*(1), 23–30. https://doi.org/10.1007/s12029-020-00518-5

Ansari, S., & Yamaoka, Y. (2019). Helicobacter pylori Virulence Factors Exploiting Gastric Colonization and its Pathogenicity. *Toxins*, *11*(11), 677. https://doi.org/10.3390/toxins11110677

Aziz, S., Rasheed, F., Akhter, T. S., Zahra, R., & König, S. (2022). Microbial Proteins in Stomach Biopsies Associated with Gastritis, Ulcer, and Gastric Cancer. *Molecules*, *27*(17), 5410. https://doi.org/10.3390/molecules27175410

Baj, J., Brzozowska, K., Forma, A., Maani, A., Sitarz, E., & Portincasa, P. (2020). Immunological Aspects of the Tumor Microenvironment and Epithelial-Mesenchymal Transition in Gastric Carcinogenesis. *International Journal of Molecular Sciences*, *21*(7), 2544. https://doi.org/10.3390/ijms21072544

Baj, J., Forma, A., Sitarz, M., Portincasa, P., Garruti, G., Krasowska, D., & Maciejewski, R. (2020). Helicobacter pylori Virulence Factors—Mechanisms of Bacterial Pathogenicity in the Gastric Microenvironment. *Cells*, *10*(1), 27. https://doi.org/10.3390/cells10010027

Bajinka, O., Tan, Y., & Simbilyabo, L. (2020). Gut Microbiome: A Guide through 'The Nuts and Bolts' for Early Researchers. *Appli Microbiol Open Access*, *6*, 170.

Bakhti, S. Z., & Latifi-Navid, S. (2021). Interplay and cooperation of Helicobacter pylori and gut microbiota in gastric carcinogenesis. *BMC Microbiology*, *21*, 1–16.

Bang, E. J., Choi, H. S., Lee, J. M., Kim, E. S., Keum, B., Jeen, Y. T., & Chun, H. J. (2022). Analysis of the gastric microbiome in gastric cancer patients and in non-tumorous patients. *Journal of Clinical Oncology*, *40*(4_suppl), 349–349. https://doi.org/10.1200/JCO.2022.40.4_suppl.349

Barra, W. F., Sarquis, D. P., Khayat, A. S., Khayat, B. C. M., Demachki, S., Anaissi, A. K. M., Ishak, G., Santos, N. P. C., Dos Santos, S. E. B., Burbano, R. R., Moreira, F. C., & De Assumpção, P. P. (2021). Gastric Cancer Microbiome. *Pathobiology*, *88*(2), 156–169. https://doi.org/10.1159/000512833

Bartelli, T. F., Albuquerque, G. E., Defelicibus, A., Serpa, M. S., Abrantes, L. L. S., Borges, R., Coimbra, F., Pelosof, A. G., Silva, I. T., Nunes, D. N., & Dias-Neto, E. (2020). Abstract B09: Unravelling the gastric microbiome in health and disease: Gastric cancer beyond *Helicobacter pylori* in a Brazilian cohort. *Cancer Research*, *80*(8_Supplement), B09–B09. https://doi.org/10.1158/1538-7445.MVC2020-B09

Bouras, E., Tsilidis, K. K., Triggi, M., Siargkas, A., Chourdakis, M., & Haidich, A.-B. (2022). Diet and Risk of Gastric Cancer: An Umbrella Review. *Nutrients*, *14*(9), 1764. https://doi.org/10.3390/nu14091764

Butt, J., Varga, M. G., Wang, T., Tsugane, S., Shimazu, T., Zheng, W., Abnet, C. C., Yoo, K.-Y., Park, S. K., & Kim, J. (2019). Smoking, Helicobacter pylori serology, and gastric cancer risk in prospective studies from China, Japan, and Korea. *Cancer Prevention Research*, *12*(10), 667–674.

Caguazango, J. C. (2020). Ecological models of gastric microbiota dysbiosis: Helicobacter pylori and gastric carcinogenesis. *Medicine in Microecology*, *3*, 100010. https://doi.org/10.1016/j.medmic.2020.100010

Caniparoli, A., Saenz Briones, P., & Rezzonico andBarg, R. A. J. S. (2022). Gastric Cancer. *Revista Argentina de Cirugia*, *26*(6), 127–128. https://doi.org/10.1201/b22898-58

Castaño-Rodríguez, N., Goh, K.-L., Fock, K. M., Mitchell, H. M., & Kaakoush, N. O. (2017). Dysbiosis of the microbiome in gastric carcinogenesis. *Scientific Reports*, *7*(1), 1–9.

Cavadas, B., Camacho, R., Ferreira, J. C., Ferreira, R. M., Figueiredo, C., Brazma, A., Fonseca, N. A., & Pereira, L. (2020). Gastric Microbiome Diversities in Gastric Cancer Patients from Europe and Asia Mimic the Human Population Structure and Are Partly Driven by Microbiome Quantitative Trait Loci. *Microorganisms*, *8*(8), 1196. https://doi.org/10.3390/microorganisms8081196

Chattopadhyay, I., Gundamaraju, R., & Rajeev, A. (2023). Diversification and deleterious microbiome in gastric cancer. *Cancer Reports*, e1878.

Chauhan, N., Tay, A. C. Y., Marshall, B. J., & Jain, U. (2019). *Helicobacter pylori* VacA, a distinct toxin exerts diverse functionalities in numerous cells: An overview. *Helicobacter*, *24*(1), e12544. https://doi.org/10.1111/hel.12544

Chen, C.-C., Liou, J.-M., Lee, Y.-C., Hong, T.-C., El-Omar, E. M., & Wu, M.-S. (2021). The interplay between Helicobacter pylori and gastrointestinal microbiota. *Gut Microbes*, *13*(1), 1909459.

Chen, X.-H., Wang, A., Chu, A.-N., Gong, Y.-H., & Yuan, Y. (2019). Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues. *Frontiers in Microbiology*, *10*, 1261. https://doi.org/10.3389/fmicb.2019.01261

Choi, I. J., Kim, C. G., Lee, J. Y., Kim, Y.-I., Kook, M.-C., Park, B., & Joo, J. (2020). Family history of gastric cancer and Helicobacter pylori treatment. *New England Journal of Medicine*, *382*(5), 427–436.

Choi, J. K., Naffouje, S. A., Goto, M., Wang, J., Christov, K., Rademacher, D. J., Green, A., Stecenko, A. A., Chakrabarty, A. M., & Das Gupta, T. K. (2023). Cross-talk between cancer and Pseudomonas aeruginosa mediates tumor suppression. *Communications Biology*, *6*(1), 16.

Choi, S., Lee, J. G., Lee, A., Eun, C. S., Han, D. S., & Park, C. H. (2019). Helicobacter pylori antibody and pepsinogen testing for predicting gastric microbiome abundance. *PLOS ONE*, *14*(12), e0225961. https://doi.org/10.1371/journal.pone.0225961

Coker, O. O., Dai, Z., Nie, Y., Zhao, G., Cao, L., Nakatsu, G., Wu, W. K., Wong, S. H., Chen, Z., & Sung, J. J. (2018). Mucosal microbiome dysbiosis in gastric carcinogenesis. *Gut*, *67*(6), 1024–1032.

Correa, P. (2018). Diet and gastric cancer. In *Diet, Nutrition, and Cancer: A Critical Evaluation* (pp. 1–10). CRC Press.

Dai, D. (2021). Interactions between gastric microbiota and metabolites in gastric cancer. *Cell Death and Disease*.

de Assumpção, P. P., Araújo, T. M. T., de Assumpção, P. B., Barra, W. F., Khayat, A. S., Assumpção, C. B., Ishak, G., Nunes, D. N., Dias-Neto, E., & Coelho, L. G. V. (2019). Suicide journey of H. pylori through gastric carcinogenesis: The role of non-H. pylori microbiome and potential consequences for clinical practice. *European Journal of Clinical Microbiology & Infectious Diseases*, *38*, 1591–1597.

Del Frari, G., & Ferreira, R. B. (2021). Microbial Blends: Terminology Overview and Introduction of the Neologism "Skopobiota." *Frontiers in Microbiology*, *12*, 659592. https://doi.org/10.3389/fmicb.2021.659592

Díaz, P., Valenzuela Valderrama, M., Bravo, J., & Quest, A. F. G. (2018). Helicobacter pylori and Gastric Cancer: Adaptive Cellular Mechanisms Involved in Disease Progression. *Frontiers in Microbiology*, *9*, 5. https://doi.org/10.3389/fmicb.2018.00005

Horanieh, R., Tamim, H., Mukherji, D., Jdiaa, S., Temraz, S., Shamseddine, Barada, K. (2020). The impact of age on prognosis in patients with gastric

cancer: Experience in a tertiary care centre. *Journal of Gastrointestinal Oncology*, *11*(6), 1233–1241. https://doi.org/10.21037/jgo-20-139

El-Sayed, A., Aleya, L., & Kamel, M. (2021). Microbiota's role in health and diseases. *Environmental Science and Pollution Research*, *28*(28), 36967–36983. https://doi.org/10.1007/s11356-021-14593-z

Engstrand, L., & Graham, D. Y. (2020). Microbiome and Gastric Cancer. *Digestive Diseases and Sciences*, *65*(3), 865–873. https://doi.org/10.1007/s10620-020-06101-z

Eslami, M., Yousefi, B., Kokhaei, P., Arabkari, V., & Ghasemian, A. (2019). Current information on the association of Helicobacter pylori with autophagy and gastric cancer. *Journal of Cellular Physiology*, *234*(9), 14800–14811.

Fahrer, J., & Christmann, M. (2023). DNA Alkylation Damage by Nitrosamines and Relevant DNA Repair Pathways. *International Journal of Molecular Sciences*, *24*(5), 4684. https://doi.org/10.3390/ijms24054684

Ferreira, R. M., Pereira-Marques, J., Pinto-Ribeiro, I., Costa, J. L., Carneiro, F., Machado, J. C., & Figueiredo, C. (2018). Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. *Gut*, *67*(2), 226–236. https://doi.org/10.1136/gutjnl-2017-314205

Feye, K. M., Baxter, M. F. A., Tellez-Isaias, G., Kogut, M. H., & Ricke, S. C. (2020). Influential factors on the composition of the conventionally raised broiler gastrointestinal microbiomes. *Poultry Science*, *99*(2), 653–659. https://doi.org/10.1016/j.psj.2019.12.013

Forgie, A. J., Fouhse, J. M., & Willing, B. P. (2019). Diet-Microbe-Host Interactions That Affect Gut Mucosal Integrity and Infection Resistance. *Frontiers in Immunology*, *10*, 1802. https://doi.org/10.3389/fimmu.2019.01802

Forma, A., Tyczyńska, M., Kędzierawski, P., Gietka, K., & Sitarz, M. (2021). Gastric carcinogenesis: A comprehensive review of the angiogenic pathways. *Clinical Journal of Gastroenterology*, *14*(1), 14–25. https://doi.org/10.1007/s12328-020-01295-1

Freire De Melo, F., Marques, H. S., Fellipe Bueno Lemos, F., Silva Luz, M., Rocha Pinheiro, S. L., De Carvalho, L. S., Souza, C. L., & Oliveira, M. V. (2022). Role of nickel-regulated small RNA in modulation of *Helicobacter pylori* virulence factors. *World Journal of Clinical Cases*, *10*(31), 11283–11291. https://doi.org/10.12998/wjcc.v10.i31.11283

Gajewski, A. Ł., Gawrysiak, M., Krupa, A., Rechciński, T., Chałubiński, M., Gonciarz, W., & Chmiela, M. (2022). Accumulation of Deleterious Effects in Gastric Epithelial Cells and Vascular Endothelial Cells In Vitro in the Milieu of Helicobacter pylori Components, 7-Ketocholesterol and Acetylsalicylic Acid. *International Journal of ... lar Sciences*, *23*(11), 6355. https://doi.org/10.3390/ijms23116355

Galura, G. M., Chavez, L. O., Robles, A., & McCallum, R. (2019). Gastroduodenal injury: Role of protective factors. *Current Gastroenterology Reports*, *21*(8), 1–7.

Glowacki, R. W. P., & Martens, E. C. (2020). In sickness and health: Effects of gut microbial metabolites on human physiology. *PLOS Pathogens*, *16*(4), e1008370. https://doi.org/10.1371/journal.ppat.1008370

Gunathilake, M. N., Lee, J., Choi, I. J., Kim, Y.-I., Ahn, Y., Park, C., & Kim, J. (2019). Association between the relative abundance of gastric microbiota and the risk of gastric cancer: A case-control study. *Scientific Reports*, *9*(1), 1–11.

Guo, Y., Cao, X.-S., Zhou, M.-G., & Yu, B. (2023). Gastric microbiota in gastric cancer: Different roles of Helicobacter pylori and other microbes. *Frontiers in Cellular and Infection Microbiology*, *12*, 1105811. https://doi.org/10.3389/fcimb.2022.1105811

Guo, Y., Zhang, Y., Gerhard, M., Gao, J.-J., Mejias-Luque, R., Zhang, L., Vieth, M., Ma, J.-L., Bajbouj, M., & Suchanek, S. (2020). Effect of Helicobacter pylori on gastrointestinal microbiota: A population-based study in Linqu, a high-risk area of gastric cancer. *Gut*, *69*(9), 1598–1607.

He, J., Hu, W., Ouyang, Q., Zhang, S., He, L., Chen, W., Li, X., & Hu, C. (2022). Helicobacter pylori infection induces stem cell-like properties in Correa cascade of gastric cancer. *Cancer Letters*, 215764.

Heo, J.-W., Kim, S.-E., & Sung, M.-K. (2021). Sex Differences in the Incidence of Obesity-Related Gastrointestinal Cancer. *International Journal of Molecular Sciences*, *22*(3), 1253. https://doi.org/10.3390/ijms22031253

Hibdon, E. S., Razumilava, N., Keeley, T. M., Wong, G., Solanki, S., Shah, Y. M., & Samuelson, L. C. (2019). Notch and mTOR signaling pathways promote human gastric cancer cell proliferation. *Neoplasia*, *21*(7), 702–712.

Hills Jr., R. D., Pontefract, B. A., Mishcon, H. R., Black, C. A., Sutton, S. C., & Theberge, C. R. (2022). Gut Microbiome: Profound Implications for Diet and Disease. *Kompass Nutrition & Dietetics*, 1–16. https://doi.org/10.1159/000523712

Holleczek, B., Schöttker, B., & Brenner, H. (2020). *Helicobacter pylori* infection, chronic atrophic gastritis and risk of stomach and esophagus cancer: Results from the prospective population-based ESTHER cohort study. *International Journal of Cancer*, *146*(10), 2773–2783. https://doi.org/10.1002/ijc.32610

Huang, K., Gao, X., Wu, L., Yan, B., Wang, Z., Zhang, X., Peng, L., Yu, J., Sun, G., & Yang, Y. (2021). Salivary Microbiota for Gastric Cancer Prediction: An Exploratory Study. *Frontiers in Cellular and Infection Microbiology*, *11*, 640309. https://doi.org/10.3389/fcimb.2021.640309

Hui, Y., Tu, C., Liu, D., Zhang, H., & Gong, X. (2023). Risk factors for gastric cancer: A comprehensive analysis of observational studies. *Frontiers in Public Health*, *10*, 892468. https://doi.org/10.3389/fpubh.2022.892468

, T., Murata-Kamiya, N., Komura, D., Tahmina, K., Wu, W., Takahashi-tsu, A., Knight, C. T., Kunita, A., Suzuki, N., Del Valle, A. A., Tsuboi, M.,

Hata, M., Hayakawa, Y., Ohnishi, N., Ueda, K., Fukayama, M., Ushiku, T., Ishikawa, S., & Hatakeyama, M. (2021). Helicobacter pylori CagA elicits BRCAness to induce genome instability that may underlie bacterial gastric carcinogenesis. *Cell Host & Microbe*, *29*(6), 941-958.e10. https://doi.org/10.1016/j.chom.2021.04.006

Israel, D. A., & Peek Jr, R. M. (2018). Mechanisms of Helicobacter pylori-induced gastric inflammation. In *Physiology of the Gastrointestinal Tract* (pp. 1517–1545). Elsevier.

Ito, N., Tsujimoto, H., Ueno, H., Xie, Q., & Shinomiya, N. (2020). Helicobacter pylori-Mediated Immunity and Signaling Transduction in Gastric Cancer. *Journal of Clinical Medicine*, *9*(11), 3699. https://doi.org/10.3390/jcm9113699

Jain, U., Saxena, K., & Chauhan, N. (2021). Helicobacter pylori induced reactive oxygen Species: A new and developing platform for detection. *Helicobacter*, *26*(3), e12796.

Joharatnam-Hogan, N., Shiu, K. K., & Khan, K. (2020). Challenges in the treatment of gastric cancer in the older patient. *Cancer Treatment Reviews*, *85*, 101980. https://doi.org/10.1016/j.ctrv.2020.101980

Kashyap, S., Pal, S., Chandan, G., Saini, V., Chakrabarti, S., Saini, N. K., Mittal, A., Thakur, V. K., Saini, A. K., & Saini, R. V. (2022). Understanding the cross-talk between human microbiota and gastrointestinal cancer for developing potential diagnostic and prognostic biomarkers. *Seminars in Cancer Biology*, *86*, 643–651. https://doi.org/10.1016/j.semcancer.2021.04.020

Kawada, T. (2019). Sex difference in patients with Helicobacter pylori infection. *European Journal of Gastroenterology & Hepatology*, *31*(8), 1070–1070. https://doi.org/10.1097/MEG.0000000000001445

Kaźmierczak-Siedlecka, K., Daca, A., Roviello, G., Catalano, M., & Połom, K. (2022). Interdisciplinary insights into the link between gut microbiome and gastric carcinogenesis—What is currently known? *Gastric Cancer*, *25*(1), 1–10.

Khali, A. B., Ouazzani, H. C., Soulaymani, A., & Quyou, A. (2019). Epidemiological Profile of Gastric Adenocarcinoma in Morocco: Evolution and Risk Factors. *European Scientific Journal ESJ*, *15*(6). https://doi.org/10.19044/esj.2019.v15n6p65

Kidane, D. (2018). Molecular Mechanisms of H. pylori-Induced DNA Double-Strand Breaks. *International Journal of Molecular Sciences*, *19*(10), 2891. https://doi.org/10.3390/ijms19102891

Krzysiek-Maczka, G., Wrobel, T., Targosz, A., Szczyrk, U., Strzalka, M., Ptak-Belowska, A., Czyz, J., & Brzozowski, T. (2019). Helicobacter pylori-activated gastric fibroblasts induce epithelial-mesenchymal transition of gastric epithelial cells in vitro in a TGF-β-dependent manner. *Helicobacter*, *24*(5), e12653.

Kumar, S., Patel, G. K., & Ghoshal, U. C. (2021). Helicobacter pylori-induced inflammation: Possible factors modulating the risk of gastric cancer. *Pathogens*, 099.

Lahner, E., Conti, L., Annibale, B., & Corleto, V. D. (2020). Current Perspectives in Atrophic Gastritis. *Current Gastroenterology Reports*, *22*(8), 38. https://doi.org/10.1007/s11894-020-00775-1

Le Guern, R., Grandjean, T., Stabler, S., Bauduin, M., Gosset, P., Kipnis, É., & Dessein, R. (2023). Gut colonisation with multidrug-resistant Klebsiella pneumoniae worsens Pseudomonas aeruginosa lung infection. *Nature Communications*, *14*(1), 78.

Lee, J. G., Kim, S. A., Eun, C. S., Han, D. S., Kim, Y. S., Choi, B. Y., Song, K. S., Kim, H. J., & Park, C. H. (2019). Impact of age on stage-specific mortality in patients with gastric cancer: A long-term prospective cohort study. *PLOS ONE*, *14*(8), e0220660. https://doi.org/10.1371/journal.pone.0220660

Lei, C., Gong, D., Zhuang, B., & Zhang, Z. (2022). Alterations in the gastric microbiota and metabolites in gastric cancer: An update review. *Frontiers in Oncology*, *12*, 960281. https://doi.org/10.3389/fonc.2022.960281

Li, Q., & Yu, H. (2020). The role of non-H. pylori bacteria in the development of gastric cancer. *American Journal of Cancer Research*, *10*(8), 2271.

Li, X., Li, S., Zhang, Z., & Huang, D. (2022). Association of multiple tumor markers with newly diagnosed gastric cancer patients: A retrospective study. *PeerJ*, *10*, e13488. https://doi.org/10.7717/peerj.13488

Li, Y., Huang, X., Tong, D., Jiang, C., Zhu, X., Wei, Z., Gong, T., & Jin, C. (2022). Relationships among microbiota, gastric cancer, and immunotherapy. *Frontiers in Microbiology*, *13*, 987763. https://doi.org/10.3389/fmicb.2022.987763

Liatsos, C., Papaefthymiou, A., Kyriakos, N., Galanopoulos, M., Doulberis, M., Giakoumis, M., Petridou, E., Mavrogiannis, C., Rokkas, T., & Kountouras, J. (2022). Helicobacter pylori, gastric microbiota and gastric cancer relationship: Unrolling the tangle. *World Journal of Gastrointestinal Oncology*, *14*(5), 959.

Lin, L., Huang, H., Liao, W., Ma, H., Liu, J., Wang, L., Huang, N., Liao, Y., & Liao, W. (2015). MACC1 supports human gastric cancer growth under metabolic stress by enhancing the Warburg effect. *Oncogene*, *34*(21), 2700–2710. https://doi.org/10.1038/onc.2014.204

Liu, C., Ng, S.-K., Ding, Y., Lin, Y., Liu, W., Wong, S. H., Sung, J. J.-Y., & Yu, J. (2022). Meta-analysis of mucosal microbiota reveals universal microbial signatures and dysbiosis in gastric carcinogenesis. *Oncogene*, *41*(28), 3599–3610.

Liu, D., Zhang, R., Chen, S., Sun, B., & Zhang, K. (2022). Analysis of gastric microbiome reveals three distinctive microbial communities associated with the occurrence of gastric cancer. *BMC Microbiology*, *22*(1), 184. https://doi.org/10.1186/s12866-022-02594-y

Liu, S., Dai, J., Lan, X., Fan, B., Dong, T., Zhang, Y., & Han, M. (2021). Intestinal bacteria are potential biomarkers and therapeutic targets for gastric cancer. *Microbial Genesis*, *151*, 104747. https://doi.org/10.1016/j.micpath.2021.104747

Liu, X., Shao, L., Liu, X., Ji, F., Mei, Y., Cheng, Y., Liu, F., Yan, C., Li, L., & Ling, Z. (2019). Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer. *EBioMedicine*, *40*, 336–348. https://doi.org/10.1016/j.ebiom.2018.12.034

Liu, Y., Zhang, Z., Wang, J., Chen, C., Tang, X., Zhu, J., & Liu, J. (2019). Metabolic reprogramming results in abnormal glycolysis in gastric cancer: A review. *OncoTargets and Therapy*, *Volume 12*, 1195–1204. https://doi.org/10.2147/OTT.S189687

Luan, X., Niu, P., Wang, W., Zhao, L., Zhang, X., Zhao, D., & Chen, Y. (2022). Sex Disparity in Patients with Gastric Cancer: A Systematic Review and Meta-Analysis. *Journal of Oncology*, *2022*, 1–16. https://doi.org/10.1155/2022/1269435

Machlowska, J., Baj, J., Sitarz, M., Maciejewski, R., & Sitarz, R. (2020). Gastric cancer: Epidemiology, risk factors, classification, genomic characteristics and treatment strategies. *International Journal of Molecular Sciences*, *21*(11), 4012.

Malfertheiner, P., Camargo, M. C., El-Omar, E., Liou, J.-M., Peek, R., Schulz, C., Smith, S. I., & Suerbaum, S. (2023). Helicobacter pylori infection. *Nature Reviews Disease Primers*, *9*(1), 19. https://doi.org/10.1038/s41572-023-00431-8

Mao, L.-Q., Zhou, Y.-L., Wang, S.-S., Chen, L., Hu, Y., Yu, L.-M., Xu, J.-M., & Lyu, B. (2021). Impact of Helicobacter pylori eradication on the gastric microbiome. *Gut Pathogens*, *13*(1), 1–13.

Martinez-Guryn, K., Leone, V., & Chang, E. B. (2019). Regional Diversity of the Gastrointestinal Microbiome. *Cell Host & Microbe*, *26*(3), 314–324. https://doi.org/10.1016/j.chom.2019.08.011

Mathebela, P., Damane, B. P., Mulaudzi, T. V., Mkhize-Khwitshana, Z. L., Gaudji, G. R., & Dlamini, Z. (2022). Influence of the Microbiome Metagenomics and Epigenomics on Gastric Cancer. *International Journal of Molecular Sciences*, *23*(22), 13750. https://doi.org/10.3390/ijms232213750

Meng, C., Bai, C., Brown, T. D., Hood, L. E., & Tian, Q. (2018). Human gut microbiota and gastrointestinal cancer. *Genomics, Proteomics & Bioinformatics*, *16*(1), 33–49.

Mitra, R., Das, L., & Das, S. K. (2019). Gut Microbiomes and Their Impact on Human Health. In T. Satyanarayana, B. N. Johri, & S. K. Das (Eds.), *Microbial Diversity in Ecosystem Sustainability and Biotechnological Applications* (pp. 355–385). Springer Singapore. https://doi.org/10.1007/978-981-13-8315-1_12

Moss, S. F. (2017). The Clinical Evidence Linking Helicobacter pylori to Gastric Cancer. *Cellular and Molecular Gastroenterology and Hepatology*, *3*(2), 183–191. https://doi.org/10.1016/j.jcmgh.2016.12.001

Mukkamalla, S. K. R., Recio-Boiles, A., & Babiker, H. M. (2023). Gastric Cancer. In *StatPearls*. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK459142/

ee, J. Y. (2017). Molecular basis of alcohol-related gastric and colon cancer. *ional Journal of Molecular Sciences*, *18*(6), 1116.

Nasr, R., Shamseddine, A., Mukherji, D., Nassar, F., & Temraz, S. (2020). The crosstalk between microbiome and immune response in gastric cancer. *International Journal of Molecular Sciences*, *21*(18), 6586.

Navashenaq, J. G., Shabgah, A. G., Banach, M., Jamialahmadi, T., Penson, P. E., Johnston, T. P., & Sahebkar, A. (2022). *The interaction of Helicobacter pylori with cancer immunomodulatory stromal cells: New insight into gastric cancer pathogenesis*. *86*, 951–959.

Ndegwa, N., Ploner, A., Andersson, A. F., Zagai, U., Andreasson, A., Vieth, M., Talley, N. J., Agreus, L., & Ye, W. (2020). Gastric Microbiota in a Low–Helicobacter pylori Prevalence General Population and Their Associations With Gastric Lesions. *Clinical and Translational Gastroenterology*, *11*(7), e00191. https://doi.org/10.14309/ctg.0000000000000191

Nguyen, H. T., Pokhrel, A. R., Nguyen, C. T., Pham, V. T. T., Dhakal, D., Lim, H. N., Jung, H. J., Kim, T.-S., Yamaguchi, T., & Sohng, J. K. (2020). Streptomyces sp. VN1, a producer of diverse metabolites including non-natural furan-type anticancer compound. *Scientific Reports*, *10*(1), 1756. https://doi.org/10.1038/s41598-020-58623-1

O'Connor, A., Bowden, A., Farrell, E., Weininger, J., Crowther, S., McNamara, D., Ridgway, P., & O'Morain, C. (2021). Risk of Progression of Gastric Intestinal Metaplasia Is Significantly Greater When Detected in Both Antrum and Body. *Digestive Diseases and Sciences*, *66*(10), 3470–3475. https://doi.org/10.1007/s10620-020-06659-8

Ohba, R., & Iijima, K. (2016). Pathogenesis and risk factors for gastric cancer after Helicobacter pylori eradication. *World Journal of Gastrointestinal Oncology*, *8*(9), 663. https://doi.org/10.4251/wjgo.v8.i9.663

Palrasu, M., Zaika, E., El-Rifai, W., Que, J., & Zaika, A. I. (2021). Role of bacterial and viral pathogens in gastric carcinogenesis. *Cancers*, *13*(8), 1878.

Park, C. H., Lee, J. G., Lee, A.-R., Eun, C. S., & Han, D. S. (2019). Network construction of gastric microbiome and organization of microbial modules associated with gastric carcinogenesis. *Scientific Reports*, *9*(1), 12444.

Park, J., Forman, D., Waskito, L., Yamaoka, Y., & Crabtree, J. (2018). Epidemiology of Helicobacter pylori and CagA-Positive Infections and Global Variations in Gastric Cancer. *Toxins*, *10*(4), 163. https://doi.org/10.3390/toxins10040163

Park, J. Y., Seo, H., Kang, C.-S., Shin, T.-S., Kim, J. W., Park, J.-M., Kim, J. G., & Kim, Y.-K. (2022). Dysbiotic change in gastric microbiome and its functional implication in gastric carcinogenesis. *Scientific Reports*, *12*(1), 4285.

Pereira-Marques, J., Ferreira, R. M., Pinto-Ribeiro, I., & Figueiredo, C. (2019). Helicobacter pylori infection, the gastric microbiome and gastric cancer. *acter Pylori in Human Diseases: Advances in Microbiology, Infectious s and Public Health Volume 11*, 195–210.

Pimentel-Nunes, P., Barros, A., Pita, I., Miranda, I., Conceição, G., Borges-Canha, M., Leite-Moreira, A. F., Libânio, D., & Dinis-Ribeiro, M. (2021). Gastric microbiome profile throughout gastric carcinogenesis: Beyond helicobacter. *Scandinavian Journal of Gastroenterology*, *56*(6), 708–716.

Ping, W., Senyan, H., Li, G., Yan, C., & Long, L. (2018). Increased Lactate in Gastric Cancer Tumor-Infiltrating Lymphocytes Is Related to Impaired T Cell Function Due to miR-34a Deregulated Lactate Dehydrogenase A. *Cellular Physiology and Biochemistry*, *49*(2), 828–836. https://doi.org/10.1159/000493110

Png, C. W., Lee, W. J. J., Chua, S. J., Zhu, F., Gastric Consortium5, Yeoh, K. G., & Zhang, Y. (2022). Mucosal microbiome associates with progression to gastric cancer. *Theranostics*, *12*(1), 48–58. https://doi.org/10.7150/thno.65302

Pramanick, R., Gazara, R. K., & Ahmad, R. (2022). *Gut Microbiome Prediction: From Current Human Evidence to Future Possibilities* [Preprint]. Microbiology. https://doi.org/10.1101/2022.11.16.516694

Puneet, Kazmi, H. R., Kumari, S., Tiwari, S., Khanna, A., & Narayan, G. (2018). Epigenetic Mechanisms and Events in Gastric Cancer-Emerging Novel Biomarkers. *Pathology & Oncology Research*, *24*(4), 757–770. https://doi.org/10.1007/s12253-018-0410-z

Pyo, J. H., Lee, H., Min, Y. W., Min, B.-H., Lee, J. H., Kim, K.-M., Yoo, H., Kim, K., Choi, Y.-H., Kim, J. J., & Kim, S. (2019). Effect of age on the clinical outcomes of patients with early gastric cancer with undifferentiated-type histology. *Surgery*, *165*(4), 802–807. https://doi.org/10.1016/j.surg.2018.11.001

Qi, Y., Sun, J., Ren, L., Cao, X., Dong, J., Tao, K., Guan, X., Cui, Y., & Su, W. (2019). Intestinal microbiota is altered in patients with gastric cancer from Shanxi Province, China. *Digestive Diseases and Sciences*, *64*, 1193–1203.

R Martin, K. (2021). Dietary Nitrates, Nitrites, and Food Safety: Risks Versus Benefits. *Acta Scientifci Nutritional Health*, *5*(6), 65–76. https://doi.org/10.31080/ASNH.2020.05.0884

Rackerby, B., Kim, H. J., Dallas, D. C., & Park, S. H. (2020). Understanding the effects of dietary components on the gut microbiome and human health. *Food Science and Biotechnology*, *29*(11), 1463–1474. https://doi.org/10.1007/s10068-020-00811-w

Rastogi, Y. R., Saini, A. K., Thakur, V. K., & Saini, R. V. (2020). New insights into molecular links between microbiota and gastrointestinal cancers: A literature review. *International Journal of Molecular Sciences*, *21*(9), 3212.

Rawla, P., & Barsouk, A. (2019). Epidemiology of gastric cancer: Global trends, risk factors and prevention. *Gastroenterology Review/Przegląd Gastroenterologiczny*, *14*(1), 26–38.

Rupp, S. (2022). Diagnostic approach to Helicobacter pylori-related gastric oncogenesis. *of Gastroenterology*. https://doi.org/10.20524/aog.2022.0725

Said, M. S., Tirthani, E., & Lesho, E. (2023). Stenotrophomonas Maltophilia. In *StatPearls*. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK572123/

Salvatori, S., Marafini, I., Laudisi, F., Monteleone, G., & Stolfi, C. (2023). Helicobacter pylori and Gastric Cancer: Pathogenetic Mechanisms. *International Journal of Molecular Sciences*, *24*(3), 2895. https://doi.org/10.3390/ijms24032895

Sauvaitre, T., Van Landuyt, J., Durif, C., Roussel, C., Sivignon, A., Chalancon, S., Uriot, O., Van Herreweghen, F., Van de Wiele, T., & Etienne-Mesmin, L. (2022). Role of mucus-bacteria interactions in Enterotoxigenic Escherichia coli (ETEC) H10407 virulence and interplay with human microbiome. *Npj Biofilms and Microbiomes*, *8*(1), 86.

Schulz, C., Schütte, K., Mayerle, J., & Malfertheiner, P. (2019). The role of the gastric bacterial microbiome in gastric cancer: *Helicobacter pylori* and beyond. *Therapeutic Advances in Gastroenterology*, *12*, 175628481989406. https://doi.org/10.1177/1756284819894062

Seol, M., Lee, Y. R., Kim, K. M., Shin, C. M., Yoon, H., Cho, J. H., Song, D. J., Kim, N., Park, Y. S., & Lee, D. H. (2019). The difference of the gut microbiota of gastric cancer in relation to *Helicobacter pylori* negativity and positivity. *Journal of Clinical Oncology*, *37*(4_suppl), 10–10. https://doi.org/10.1200/JCO.2019.37.4_suppl.10

Sheweita, S. A., & Alsamghan, A. S. (2020). Molecular mechanisms contributing bacterial infections to the incidence of various types of cancer. *Mediators of Inflammation*, *2020*.

Shirazi, M. S. R., Al-Alo, K., Al-Yasiri, M. H., Lateef, Z. M., & Ghasemian, A. (2020). Microbiome dysbiosis and predominant bacterial species as human cancer biomarkers. *Journal of Gastrointestinal Cancer*, *51*, 725–728.

Sitarz, R., Skierucha, M., Mielko, J., Offerhaus, G. J. A., Maciejewski, R., & Polkowski, W. P. (2018). Gastric cancer: Epidemiology, prevention, classification, and treatment. *Cancer Management and Research*, *10*, 239.

Smet, A., Kupcinskas, J., Link, A., Hold, G. L., & Bornschein, J. (2022). The role of microbiota in gastrointestinal cancer and cancer treatment: Chance or curse? *Cellular and Molecular Gastroenterology and Hepatology*, *13*(3), 857–874.

Smirnova, O. V., Sinyakov, A. A., & Kasparov, E. V. (2022). The Role of Immunoglobulin G (IgG), IgA and IgE—Antibodies against Helicobacter pylori in the Development of Oxidative Stress in Patients with Chronic Gastritis. *Biomedicines*, *10*(8), 2053. https://doi.org/10.3390/biomedicines10082053

Song, H., Ekheden, I. G., Ploner, A., Ericsson, J., Nyren, O., & Ye, W. (2018). Family history of gastric mucosal abnormality and the risk of gastric cancer: A population-based observational study. *International Journal of Epidemiology*, *47*(2), 440–449.

Wu, F., & Chen, Y. (2020). The role of gastric microbiota in gastric cancer. *crobes*, *11*(5), 1220–1230. https://doi.org/10.1080/19490976.2020.1762520

Sukri, A., Hanafiah, A., Kosai, N. R., Mohammed Taher, M., & Mohamed, R. (2022). New insight on the role of Helicobacter pylori cagA in the expression of cell surface antigens with important biological functions in gastric carcinogenesis. *Helicobacter*, *27*(5), e12913.

Sun, Q.-H., Zhang, J., Shi, Y.-Y., Zhang, J., Fu, W.-W., & Ding, S.-G. (2022). Microbiome changes in the gastric mucosa and gastric juice in different histological stages of *Helicobacter pylori* -negative gastric cancers. *World Journal of Gastroenterology*, *28*(3), 365–380. https://doi.org/10.3748/wjg.v28.i3.365

Sung, J., Kim, N., Lee, J., Hwang, Y.-J., Kim, H. W., Chung, J. W., Kim, J.-W., & Lee, D. H. (2018). Associations among Gastric Juice pH, Atrophic Gastritis, Intestinal Metaplasia and *Helicobacter pylori* Infection. *Gut and Liver*, *12*(2), 158–164. https://doi.org/10.5009/gnl17063

Takahashi-Kanemitsu, A., Knight, C. T., & Hatakeyama, M. (2020). Molecular anatomy and pathogenic actions of Helicobacter pylori CagA that underpin gastric carcinogenesis. *Cellular & Molecular Immunology*, *17*(1), 50–63.

Tamma, R., Annese, T., Ruggieri, S., Marzullo, A., Nico, B., & Ribatti, D. (2018). VEGFA and VEGFR2 RNAscope determination in gastric cancer. *Journal of Molecular Histology*, *49*(4), 429–435. https://doi.org/10.1007/s10735-018-9777-0

Thapa, S., Fischbach, L. A., Delongchamp, R., Faramawi, M. F., & Orloff, M. (2019). Association between Dietary Salt Intake and Progression in the Gastric Precancerous Process. *Cancers*, *11*(4), 467. https://doi.org/10.3390/cancers11040467

Thrastardottir, T. O., Copeland, V. J., & Constantinou, C. (2022). The Association Between the Gut Microbiome, Nutritional Habits, Antibiotics, and Gastric Cancer: A Scoping Review. *Current Nutrition Reports*, *11*(1), 19–38.

Thrift, A. P., & El-Serag, H. B. (2020). Burden of gastric cancer. *Clinical Gastroenterology and Hepatology*, *18*(3), 534–542.

Ticer, T., Ellis, T., & Engevik, M. A. (2022). *Klebsiella pneumoniae* utilizes intestinal mucus to increase fitness in the gastrointestinal tract. *The FASEB Journal*, *36*(S1), fasebj.2022.36.S1.R6048. https://doi.org/10.1096/fasebj.2022.36.S1.R6048

Usui, G., Matsusaka, K., Mano, Y., Urabe, M., Funata, S., Fukayama, M., Ushiku, T., & Kaneda, A. (2021). DNA Methylation and Genetic Aberrations in Gastric Cancer. *Digestion*, *102*(1), 25–32. https://doi.org/10.1159/000511243

Vanella, G., Archibugi, L., Stigliano, S., & Capurso, G. (2019). Alcohol and gastrointestinal cancers. *Current Opinion in Gastroenterology*, *35*(2), 107–113.

Vinasco, K., Mitchell, H. M., Kaakoush, N. O., & Castaño-Rodríguez, N. (2019). Microbial carcinogenesis: Lactic acid bacteria in gastric cancer. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*, *1872*(2), 188309. loi.org/10.1016/j.bbcan.2019.07.004

Waldum, H., & Fossmark, R. (2021). Gastritis, gastric polyps and gastric cancer. *International Journal of Molecular Sciences*, *22*(12), 6548.

Wang, D., Zhang, T., Lu, Y., Wang, C., Wu, Y., Li, J., Tao, Y., Deng, L., Zhang, X., & Ma, J. (2022). Helicobacter pylori infection affects the human gastric microbiome, as revealed by metagenomic sequencing. *FEBS Open Bio*, *12*(6), 1188–1196.

Wang, L.-L., Liu, J.-X., Yu, X.-J., Si, J.-L., Zhai, Y.-X., & Dong, Q.-J. (2018). Microbial community reshaped in gastric cancer. *European Review for Medical & Pharmacological Sciences*, *22*(21).

Wang, Z., Gao, X., Zeng, R., Wu, Q., Sun, H., Wu, W., Zhang, X., Sun, G., Yan, B., Wu, L., Ren, R., Guo, M., Peng, L., & Yang, Y. (2020). Changes of the Gastric Mucosal Microbiome Associated With Histological Stages of Gastric Carcinogenesis. *Frontiers in Microbiology*, *11*, 997. https://doi.org/10.3389/fmicb.2020.00997

Weng, M.-T., Chiu, Y.-T., Wei, P.-Y., Chiang, C.-W., Fang, H.-L., & Wei, S.-C. (2019). Microbiota and gastrointestinal cancer. *Journal of the Formosan Medical Association*, *118*, S32–S41.

Wu, T., Xu, F., Su, C., Li, H., Lv, N., Liu, Y., Gao, Y., Lan, Y., & Li, J. (2020). Alterations in the gut microbiome and cecal metabolome during Klebsiella pneumoniae-induced pneumosepsis. *Frontiers in Immunology*, *11*, 1331.

Xi, J., Li, Y., Zhang, H., & Bai, Z. (2023). Dynamic variations of the gastric microbiota: Key therapeutic points in the reversal of Correa's cascade. *International Journal of Cancer*, *152*(6), 1069–1084.

Yang, J., Zhou, X., Liu, X., Ling, Z., & Ji, F. (2021). Role of the gastric microbiome in gastric cancer: From carcinogenesis to treatment. *Frontiers in Microbiology*, *12*, 641322.

Yang, Y., Dai, D., Jin, W., Huang, Y., Zhang, Y., Chen, Y., Wang, W., Lin, W., Chen, X., & Zhang, J. (2022). Microbiota and metabolites alterations in proximal and distal gastric cancer patients. *Journal of Translational Medicine*, *20*(1), 1–14.

Yao, X., & Smolka, A. J. (2019). Gastric Parietal Cell Physiology and Helicobacter pylori–Induced Disease. *Gastroenterology*, *156*(8), 2158–2173. https://doi.org/10.1053/j.gastro.2019.02.036

Yoo, J. Y., Groer, M., Dutra, S. V. O., Sarkar, A., & McSkimming, D. I. (2020). Gut microbiota and immune system interactions. *Microorganisms*, *8*(10), 1587.

Yoo, W., & Byndloss, M. X. (2019). How to thrive in the inflamed gut. *Nature Microbiology*, *5*(1), 10–11. https://doi.org/10.1038/s41564-019-0642-z

Yuan, L.-W. (2016). Glucose metabolism in gastric cancer: The cutting-edge. *World Journal of Gastroenterology*, *22*(6), 2046. https://doi.org/10.3748/wjg.v22.i6.2046

Yusefi, A. R., Lankarani, K. B., Bastani, P., Radinmanesh, M., & Kavosi, Z. (2018). Risk factors for gastric cancer: A systematic review. *Asian Pacific Journal of Cancer ion: APJCP*, *19*(3), 591.

Zeng, M. Y., Inohara, N., & Nuñez, G. (2017). Mechanisms of inflammation-driven bacterial dysbiosis in the gut. *Mucosal Immunology*, *10*(1), 18–26. https://doi.org/10.1038/mi.2016.75

Zhang, L., Zhao, M., & Fu, X. (2023). Gastric microbiota dysbiosis and Helicobacter pylori infection. *Frontiers in Microbiology*, *14*, 966.

Zhang, X.-Y., Zhang, P.-Y., & Aboul-Soud, M. A. (2017). From inflammation to gastric cancer: Role of Helicobacter pylori. *Oncology Letters*, *13*(2), 543–548.

Zhao, L., Liu, Y., Zhang, S., Wei, L., Cheng, H., Wang, J., & Wang, J. (2022). Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer. *Cell Death & Disease*, *13*(4), 378. https://doi.org/10.1038/s41419-022-04821-w

Zhou, C., Bisseling, T. M., van der Post, R. S., & Boleij, A. (2023). The influence of Helicobacter pylori, proton pump inhibitor, and obesity on the gastric microbiome in relation to gastric cancer development. *Computational and Structural Biotechnology Journal*.

Zhou, S., Li, C., Liu, L., Yuan, Q., Miao, J., Wang, H., Ding, C., & Guan, W. (2023). Gastric microbiota: An emerging player in gastric cancer. *Frontiers in Microbiology*, *14*, 1130001. https://doi.org/10.3389/fmicb.2023.1130001

Zhou, Y.-J., Lu, X.-F., Meng, J.-L., Wang, Q.-W., Chen, J.-N., Zhang, Q.-W., Zheng, K. I., Rocha, C. S., Martins, C. B., Yan, F.-R., & Li, X.-B. (2021). Specific epigenetic age acceleration patterns among four molecular subtypes of gastric cancer and their prognostic value. *Epigenomics*, *13*(10), 767–778. https://doi.org/10.2217/epi-2020-0290

LAMPIRAN

```
GET
  FILE='C:\Users\Ariiq\Downloads\dataset dr rini.sav'.
DATASET NAME DataSet1 WINDOW=FRONT.
FREQUENCIES VARIABLES=pcr umur_kat jenis_kelamin histopatologi h.pylori
  /ORDER=ANALYSIS.
```

Frequencies

Notes

Output Created		22-JAN-2024 20:21:01
Comments		
Input	Data	C:\Users\Ariiq\Downloads\dataset dr rini.sav
	Active Dataset	DataSet1
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	119
Missing Value Handling	Definition of Missing	User-defined missing values are treated as missing.
	Cases Used	Statistics are based on all cases with valid data.
Syntax		FREQUENCIES VARIABLES=pcr umur_kat jenis_kelamin histopatologi h.pylori /ORDER=ANALYSIS.

Resources	Processor Time	00:00:00,00
	Elapsed Time	00:00:00,00

[DataSet1] C:\Users\Ariiq\Downloads\dataset dr rini.sav

Statistics

		pcr	umur_kat	jenis_kelamin	histopatologi	h.pylori
N	Valid	119	119	119	119	119
	Missing	0	0	0	0	0

Frequency Table

pcr

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Acinetobacter baumanii	6	5.0	5.0	5.0
	Streptomyces	3	2.5	2.5	7.6
	Acinetobacter bereziniae	10	8.4	8.4	16.0
	Acinetobacter guilloniae	3	2.5	2.5	18.5
	Mannheimia haemolytica	1	.8	.8	19.3
	Escherichia coli	8	6.7	6.7	26.1
	Lactobacillus plantarum	1	.8	.8	26.9
	Bacteriodetes bacterium	4	3.4	3.4	30.3

Pseudomonas stutzeri	1	.8	.8	31.1
Klebsiella pneumoniae	6	5.0	5.0	36.1
Bacillus sp.	1	.8	.8	37.0
Prevotella denticola	4	3.4	3.4	40.3
Acinetobacter sp.	13	10.9	10.9	51.3
Vibrio cholerae	1	.8	.8	52.1
Haemophilus influenzae	1	.8	.8	52.9
Rhizobium sp.	1	.8	.8	53.8
Acinetobacter calcoaceticus	1	.8	.8	54.6
Acinetobacter junii	1	.8	.8	55.5
Helicobacter pylori	1	.8	.8	56.3
Photobacterium ganghwense	1	.8	.8	57.1
Citrobacter youngae	1	.8	.8	58.0
Acinetobater schindleri	1	.8	.8	58.8
Agrobacterium tumafaciens	2	1.7	1.7	60.5
Bacteriodes fragilis	1	.8	.8	61.3
Pseudomonas flourescens	1	.8	.8	62.2
Enterobacter sp.	5	4.2	4.2	66.4
Shigella sonnei	1	.8	.8	67.2
Escherichia sp.	3	2.5	2.5	69.7
Vibrio campbelii	1	.8	.8	70.6
Prevotella jejuni	1	.8	.8	71.4
Pseudomonas plecoglossicida	1	.8	.8	72.3
Pseudomonas sp.	1	.8	.8	73.1
Pseudomonas mosselii	1	.8	.8	73.9

	Frequency	Percent	Valid Percent	Cumulative Percent
Atopobium sp.	1	.8	.8	74.8
Burkholderia sp.	1	.8	.8	75.6
Enterobacter cloacae	1	.8	.8	76.5
Stenotrophomonas maltophila	21	17.6	17.6	94.1
Citrobacter freundii	2	1.7	1.7	95.8
Salmonella typhi	1	.8	.8	96.6
Staphylococcus sp.	1	.8	.8	97.5
Enterobacter mori	1	.8	.8	98.3
Vibrio sp.	1	.8	.8	99.2
Serratia proteamaculans	1	.8	.8	100.0
Total	119	100.0	100.0	

umur_kat

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	> 45	83	69.7	69.7	69.7
	< 45	36	30.3	30.3	100.0
	Total	119	100.0	100.0	

jenis_kelamin

	Frequency	Percent	Valid Percent	Cumulative Percent
laki-laki	73	61.3	61.3	61.3

		Frequency	Percent	Valid Percent	Cumulative Percent
	perempuan	46	38.7	38.7	100.0
	Total	119	100.0	100.0	

histopatologi

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Karsinoma	17	14.3	14.3	14.3
	Ulkus	34	28.6	28.6	42.9
	Gastritis	68	57.1	57.1	100.0
	Total	119	100.0	100.0	

h.pylori

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Infeksi ada	15	12.6	12.6	12.6
	tidak ada	104	87.4	87.4	100.0
	Total	119	100.0	100.0	

```
DESCRIPTIVES VARIABLES=umur_num
    [STICS=MEAN STDDEV MIN MAX.
```

Descriptives

Notes

Output Created		22-JAN-2024 20:21:25
Comments		
Input	Data	C:\Users\Ariiq\Downloads\dataset dr rini.sav
	Active Dataset	DataSet1
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	119
Missing Value Handling	Definition of Missing	User defined missing values are treated as missing.
	Cases Used	All non-missing data are used.
Syntax		DESCRIPTIVES VARIABLES=umur_num /STATISTICS=MEAN STDDEV MIN MAX.
	Processor Time	00:00:00,00
	Elapsed Time	00:00:00,02

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
umur_num	119	21.00	82.00	50.9832	13.32640
Valid N (listwise)	119				

```
CROSSTABS
  /TABLES=umur_kat jenis_kelamin h.pylori BY histopatologikanker histononkanker
  /FORMAT=AVALUE TABLES
  /STATISTICS=CHISQ RISK
  /CELLS=COUNT ROW
  /COUNT ROUND CELL.
```

Crosstabs

Notes

Output Created		22-JAN-2024 20:24:19
Comments		
Input	Data	C:\Users\Ariiq\Downloads\dataset dr rini.sav
	Active Dataset	DataSet1
	Filter	<none>
	Weight	<none>

	Split File	<none>
	N of Rows in Working Data File	119
Missing Value Handling	Definition of Missing	User-defined missing values are treated as missing.
	Cases Used	Statistics for each table are based on all the cases with valid data in the specified range(s) for all variables in each table.

Syntax		CROSSTABS
		  /TABLES=umur_kat jenis_kelamin h.pylori BY histopatologikanker histononkanker
		  /FORMAT=AVALUE TABLES
		  /STATISTICS=CHISQ RISK
		  /CELLS=COUNT ROW
		  /COUNT ROUND CELL.

Resources	Processor Time	00:00:00,00
	Elapsed Time	00:00:00,02
	Dimensions Requested	2
	Cells Available	349496

Case Processing Summary

	Cases		
	Valid	Missing	Total

	N	Percent	N	Percent	N	Percent
umur_kat * histopatologikanker	119	100.0%	0	0.0%	119	100.0%
umur_kat * histononkanker	119	100.0%	0	0.0%	119	100.0%
jenis_kelamin * histopatologikanker	119	100.0%	0	0.0%	119	100.0%
jenis_kelamin * histononkanker	119	100.0%	0	0.0%	119	100.0%
h.pylori * histopatologikanker	119	100.0%	0	0.0%	119	100.0%
h.pylori * histononkanker	119	100.0%	0	0.0%	119	100.0%

umur_kat * histopatologikanker

Crosstab

			histopatologikanker		Total
			kanker	non kanker	
umur_kat	> 45	Count	15	68	83
		% within umur_kat	18.1%	81.9%	100.0%
	< 45	Count	2	34	36
		% within umur_kat	5.6%	94.4%	100.0%
		Count	17	102	119
		% within umur_kat	14.3%	85.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	3.213[a]	1	.073		
Continuity Correction[b]	2.272	1	.132		
Likelihood Ratio	3.726	1	.054		
Fisher's Exact Test				.091	.060
Linear-by-Linear Association	3.186	1	.074		
N of Valid Cases	119				

a. 0 cells (,0%) have expected count less than 5. The minimum expected count is 5,14.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for umur_kat (> 45 / < 45)	3.750	.811	17.349
For cohort histopatologikanker = kanker	3.253	.784	13.493
histopatologikanker = r	.867	.763	.986
Cases	119		

umur_kat * histononkanker

Crosstab

			histononkanker			
			kanker	ulkus	gastritis	Total
umur_kat	> 45	Count	15	31	37	83
		% within umur_kat	18.1%	37.3%	44.6%	100.0%
	< 45	Count	2	3	31	36
		% within umur_kat	5.6%	8.3%	86.1%	100.0%
Total		Count	17	34	68	119
		% within umur_kat	14.3%	28.6%	57.1%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
hi-Square	17.733[a]	2	.000
Ratio	19.544	2	.000
Linear Association	13.708	1	.000

N of Valid Cases	119		

a. 0 cells (,0%) have expected count less than 5. The minimum expected count is 5,14.

Risk Estimate

	Value
Odds Ratio for umur_kat (> 45 / < 45)	a

a. Risk Estimate statistics cannot be computed. They are only computed for a 2*2 table without empty cells.

jenis_kelamin * histopatologikanker

Crosstab

			histopatologikanker		
			kanker	non kanker	Total
nin	laki-laki	Count	15	58	73
		% within jenis_kelamin	20.5%	79.5%	100.0%
	perempuan	Count	2	44	46

		4.3%	95.7%	100.0%
Total	Count	17	102	119
	% within jenis_kelamin	14.3%	85.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	6.048a	1	.014		
Continuity Correctionb	4.797	1	.029		
Likelihood Ratio	7.000	1	.008		
Fisher's Exact Test				.015	.011
Linear-by-Linear Association	5.997	1	.014		
N of Valid Cases	119				

a. 0 cells (,0%) have expected count less than 5. The minimum expected count is 6,57.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
o for jenis_kelamin berempuan)	5.690	1.236	26.185

For cohort histopatologikanker = kanker	4.726	1.133	19.720
For cohort histopatologikanker = non kanker	.831	.728	.948
N of Valid Cases	119		

jenis_kelamin * histononkanker

Crosstab

			histononkanker			Total
			kanker	ulkus	gastritis	
jenis_kelamin	laki-laki	Count	15	21	37	73
		% within jenis_kelamin	20.5%	28.8%	50.7%	100.0%
	perempuan	Count	2	13	31	46
		% within jenis_kelamin	4.3%	28.3%	67.4%	100.0%
Total		Count	17	34	68	119
		% within jenis_kelamin	14.3%	28.6%	57.1%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	6.565[a]	2	.038
Likelihood Ratio	7.502	2	.023
Linear-by-Linear Association	5.710	1	.017
N of Valid Cases	119		

a. 0 cells (,0%) have expected count less than 5. The minimum expected count is 6,57.

Risk Estimate

	Value
Odds Ratio for jenis_kelamin (laki-laki / perempuan)	[a]

a. Risk Estimate statistics cannot be computed. They are only computed for a 2*2 table without empty cells.

h.pylori * histopatologikanker

Crosstab

| | | | histopatologikanker | | |
			kanker	non kanker	Total
h.pylori	Infeksi ada	Count	4	11	15
		% within h.pylori	26.7%	73.3%	100.0%
	tidak ada	Count	13	91	104
		% within h.pylori	12.5%	87.5%	100.0%
Total		Count	17	102	119
		% within h.pylori	14.3%	85.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	2.149ᵃ	1	.143		
Continuity Correctionᵇ	1.147	1	.284		
Likelihood Ratio	1.842	1	.175		
Fisher's Exact Test				.227	.142
Linear-by-Linear Association	2.131	1	.144		
N of Valid Cases	119				

1 cells (25,0%) have expected count less than 5. The minimum expected count is 2,14.

ed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for h.pylori (Infeksi ada / tidak ada)	2.545	.705	9.187
For cohort histopatologikanker = kanker	2.133	.800	5.691
For cohort histopatologikanker = non kanker	.838	.612	1.147
N of Valid Cases	119		

h.pylori * histononkanker

Crosstab

			histononkanker			Total
			kanker	ulkus	gastritis	
h.pylori	Infeksi ada	Count	4	4	7	15
		% within h.pylori	26.7%	26.7%	46.7%	100.0%
	tidak ada	Count	13	30	61	104
		% within h.pylori	12.5%	28.8%	58.7%	100.0%
		Count	17	34	68	119
		% within h.pylori	14.3%	28.6%	57.1%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	2.193[a]	2	.334
Likelihood Ratio	1.892	2	.388
Linear-by-Linear Association	1.676	1	.195
N of Valid Cases	119		

a. 2 cells (33,3%) have expected count less than 5. The minimum expected count is 2,14.

Risk Estimate

	Value
Odds Ratio for h.pylori (Infeksi ada / tidak ada)	[a]

a. Risk Estimate statistics cannot be computed. They are only computed for a 2*2 table without empty cells.

BS
ES=acinetobacter_baumannii acinetobacter_bereziniae escherichia_coli
lla_pneumoniae
netobacter_sp enterobacter_sp stenotrophomonas acinetobacter_gabung escherichia_gabung

```
  enterobacter_gabung pseudomonas_gabung BY histopatologikanker
/FORMAT=AVALUE TABLES
/STATISTICS=CHISQ RISK
/CELLS=COUNT ROW
/COUNT ROUND CELL.
```

Crosstabs

Notes

Output Created		22-JAN-2024 20:27:39
Comments		
Input	Data	C:\Users\Ariiq\Downloads\dataset dr rini.sav
	Active Dataset	DataSet1
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	119
	Value Handling	Definition of Missing	User-defined missing values are treated as missing.

Cases Used	Statistics for each table are based on all the cases with valid data in the specified range(s) for all variables in each table.

Syntax	CROSSTABS
	
	/TABLES=acinetobacter_bauman nii acinetobacter_bereziniae escherichia_coli klebsiella_pneumoniae
	  acinetobacter_sp enterobacter_sp stenotrophomonas acinetobacter_gabung escherichia_gabung
	  enterobacter_gabung pseudomonas_gabung BY histopatologikanker
	 /FORMAT=AVALUE TABLES
	 /STATISTICS=CHISQ RISK
	 /CELLS=COUNT ROW
	 /COUNT ROUND CELL.

Resources	Processor Time	00:00:00,00
	Elapsed Time	00:00:00,02
	Dimensions Requested	2
	Cells Available	349496

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
acinetobacter_baumannii * histopatologikanker	119	100.0%	0	0.0%	119	100.0%
acinetobacter_bereziniae * histopatologikanker	119	100.0%	0	0.0%	119	100.0%
escherichia_coli * histopatologikanker	119	100.0%	0	0.0%	119	100.0%
klebsiella_pneumoniae * histopatologikanker	119	100.0%	0	0.0%	119	100.0%
acinetobacter_sp * histopatologikanker	119	100.0%	0	0.0%	119	100.0%
enterobacter_sp * histopatologikanker	119	100.0%	0	0.0%	119	100.0%
stenotrophomonas * histopatologikanker	119	100.0%	0	0.0%	119	100.0%
acinetobacter_gabung * histopatologikanker	119	100.0%	0	0.0%	119	100.0%
a_gabung * gikanker	119	100.0%	0	0.0%	119	100.0%
er_gabung * gikanker	119	100.0%	0	0.0%	119	100.0%

pseudomonas_gabung * histopatologikanker	119	100.0%	0	0.0%	119	100.0%

acinetobacter_baumannii * histopatologikanker

Crosstab

			histopatologikanker		Total
			kanker	non kanker	
acinetobacter_baumannii	dominan	Count	0	6	6
		% within acinetobacter_baumannii	0.0%	100.0%	100.0%
	tidak dominan	Count	17	96	113
		% within acinetobacter_baumannii	15.0%	85.0%	100.0%
Total		Count	17	102	119
		% within acinetobacter_baumannii	14.3%	85.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.053[a]	1	.305		
Continuity Correction[b]	.183	1	.669		
Likelihood Ratio	1.902	1	.168		
Fisher's Exact Test				.592	.388
Linear-by-Linear Association	1.044	1	.307		
N of Valid Cases	119				

a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is ,86.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
For cohort histopatologikanker = non kanker	1.177	1.089	1.272
N of Valid Cases	119		

bacter_bereziniae * histopatologikanker

Crosstab

			histopatologikanker		
			kanker	non kanker	Total
acinetobacter_bereziniae	dominan	Count	0	10	10
		% within acinetobacter_bereziniae	0.0%	100.0%	100.0%
	tidak dominan	Count	17	92	109
		% within acinetobacter_bereziniae	15.6%	84.4%	100.0%
Total		Count	17	102	119
		% within acinetobacter_bereziniae	14.3%	85.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.820[a]	1	.177		
Continuity Correction[b]	.769	1	.381		
Likelihood Ratio	3.232	1	.072		
xact Test				.354	.200
Linear Association	1.804	1	.179		
Cases	119				

a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is 1,43.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
For cohort histopatologikanker = non kanker	1.185	1.093	1.284
N of Valid Cases	119		

escherichia_coli * histopatologikanker

Crosstab

			histopatologikanker		Total
			kanker	non kanker	
escherichia_coli	dominan	Count	1	7	8
		% within escherichia_coli	12.5%	87.5%	100.0%
	tidak dominan	Count	16	95	111
		% within escherichia_coli	14.4%	85.6%	100.0%
		Count	17	102	119

% within escherichia_coli		14.3%	85.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.022[a]	1	.881		
Continuity Correction[b]	.000	1	1.000		
Likelihood Ratio	.023	1	.879		
Fisher's Exact Test				1.000	.680
Linear-by-Linear Association	.022	1	.882		
N of Valid Cases	119				

a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is 1,14.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for escherichia_coli tidak dominan)	.848	.098	7.364
histopatologikanker =	.867	.131	5.732

For cohort histopatologikanker = non kanker	1.022	.778	1.343
N of Valid Cases	119		

klebsiella_pneumoniae * histopatologikanker

Crosstab

			histopatologikanker		Total
			kanker	non kanker	
klebsiella_pneumoniae	dominan	Count	1	5	6
		% within klebsiella_pneumoniae	16.7%	83.3%	100.0%
	tidak dominan	Count	16	97	113
		% within klebsiella_pneumoniae	14.2%	85.8%	100.0%
Total		Count	17	102	119
		% within klebsiella_pneumoniae	14.3%	85.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)

Pearson Chi-Square	.029[a]	1	.864		
Continuity Correction[b]	.000	1	1.000		
Likelihood Ratio	.028	1	.867		
Fisher's Exact Test				1.000	.612
Linear-by-Linear Association	.029	1	.865		
N of Valid Cases	119				

a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is ,86.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for klebsiella_pneumoniae (dominan / tidak dominan)	1.213	.133	11.066
For cohort histopatologikanker = kanker	1.177	.186	7.455
For cohort histopatologikanker = non kanker	.971	.674	1.399
N of Valid Cases	119		

bacter_sp * histopatologikanker

Crosstab

| | | | histopatologikanker | | |
			kanker	non kanker	Total
acinetobacter_sp	dominan	Count	1	12	13
		% within acinetobacter_sp	7.7%	92.3%	100.0%
	tiidak dominan	Count	16	90	106
		% within acinetobacter_sp	15.1%	84.9%	100.0%
Total		Count	17	102	119
		% within acinetobacter_sp	14.3%	85.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.518[a]	1	.472		
Continuity Correction[b]	.090	1	.764		
Likelihood Ratio	.596	1	.440		
Fisher's Exact Test				.690	.414
Linear Association	.514	1	.474		
Cases	119				

25,0%) have expected count less than 5. The minimum expected count is 1,86.

ed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for acinetobacter_sp (dominan / tiidak dominan)	.469	.057	3.859
For cohort histopatologikanker = kanker	.510	.073	3.534
For cohort histopatologikanker = non kanker	1.087	.911	1.297
N of Valid Cases	119		

enterobacter_sp * histopatologikanker

Crosstab

			histopatologikanker		Total
			kanker	non kanker	
er_sp	dominan	Count	1	4	5
		% within enterobacter_sp	20.0%	80.0%	100.0%
	tidak	Count	16	98	114

		14.0%	86.0%	100.0%
Total	Count	17	102	119
	% within enterobacter_sp	14.3%	85.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.139[a]	1	.709		
Continuity Correction[b]	.000	1	1.000		
Likelihood Ratio	.127	1	.722		
Fisher's Exact Test				.544	.544
Linear-by-Linear Association	.138	1	.710		
N of Valid Cases	119				

a. 2 cells (50,0%) have expected count less than 5. The minimum expected count is ,71.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
for enterobacter_sp tidak)	1.531	.161	14.588

For cohort histopatologikanker = kanker	1.425	.233	8.716
For cohort histopatologikanker = non kanker	.931	.597	1.451
N of Valid Cases	119		

stenotrophomonas * histopatologikanker

Crosstab

			histopatologikanker		
			kanker	non kanker	Total
stenotrophomonas	dominan	Count	6	14	20
		% within stenotrophomonas	30.0%	70.0%	100.0%
	tidak dominan	Count	11	88	99
		% within stenotrophomonas	11.1%	88.9%	100.0%
Total		Count	17	102	119
		% within stenotrophomonas	14.3%	85.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	4.848[a]	1	.028		
Continuity Correction[b]	3.428	1	.064		
Likelihood Ratio	4.104	1	.043		
Fisher's Exact Test				.039	.039
Linear-by-Linear Association	4.807	1	.028		
N of Valid Cases	119				

a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is 2,86.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for stenotrophomonas (dominan / tidak dominan)	3.429	1.093	10.758
For cohort histopatologikanker = kanker	2.700	1.130	6.451
For cohort histopatologikanker = r	.788	.586	1.058
Cases	119		

acinetobacter_gabung * histopatologikanker

Crosstab

| | | | histopatologikanker | | |
			kanker	non kanker	Total
acinetobacter_gabung	dominan	Count	1	34	35
		% within acinetobacter_gabung	2.9%	97.1%	100.0%
	tidak dominan	Count	16	68	84
		% within acinetobacter_gabung	19.0%	81.0%	100.0%
Total		Count	17	102	119
		% within acinetobacter_gabung	14.3%	85.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
hi-Square	5.289ᵃ	1	.021		
Correctionᵇ	4.049	1	.044		
Ratio	6.724	1	.010		
xact Test				.022	.015

Linear-by-Linear Association	5.244	1	.022		
N of Valid Cases	119				

a. 0 cells (,0%) have expected count less than 5. The minimum expected count is 5,00.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for acinetobacter_gabung (dominan / tidak dominan)	.125	.016	.983
For cohort histopatologikanker = kanker	.150	.021	1.088
For cohort histopatologikanker = non kanker	1.200	1.066	1.351
N of Valid Cases	119		

escherichia_gabung * histopatologikanker

Crosstab

			histopatologikanker		
			kanker	non kanker	Total
escherichia_gabung	dominan	Count	1	10	11
		% within escherichia_gabung	9.1%	90.9%	100.0%
	tidak dominan	Count	16	92	108
		% within escherichia_gabung	14.8%	85.2%	100.0%
Total		Count	17	102	119
		% within escherichia_gabung	14.3%	85.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.267[a]	1	.605		
Continuity Correction[b]	.004	1	.948		
Likelihood Ratio	.297	1	.586		
Fisher's Exact Test				1.000	.512
Linear-by-Linear Association	.265	1	.607		
N of Valid Cases	119				

a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is 1,57.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for escherichia_gabung (dominan / tidak dominan)	.575	.069	4.805
For cohort histopatologikanker = kanker	.614	.090	4.197
For cohort histopatologikanker = non kanker	1.067	.871	1.307
N of Valid Cases	119		

enterobacter_gabung * histopatologikanker

Crosstab

			histopatologikanker		Total
			kanker	non kanker	
enterobacter_gabung	domina	Count	2	5	7
		% within enterobacter_gabung	28.6%	71.4%	100.0%
	tidak dominan	Count	15	97	112
		% within enterobacter_gabung	13.4%	86.6%	100.0%
		Count	17	102	119
		% within enterobacter_gabung	14.3%	85.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.240ª	1	.266		
Continuity Correctionᵇ	.310	1	.578		
Likelihood Ratio	1.024	1	.312		
Fisher's Exact Test				.262	.262
Linear-by-Linear Association	1.229	1	.268		
N of Valid Cases	119				

a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is 1,00.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for enterobacter_gabung (domina / ___ nan)	2.587	.460	14.556
___ histopatologikanker =	2.133	.604	7.539

For cohort histopatologikanker = non kanker	.825	.513	1.325
N of Valid Cases	119		

pseudomonas_gabung * histopatologikanker

Crosstab

			histopatologikanker		Total
			kanker	non kanker	
pseudomonas_gabung	dominan	Count	0	5	5
		% within pseudomonas_gabung	0.0%	100.0%	100.0%
	tidak dominan	Count	17	97	114
		% within pseudomonas_gabung	14.9%	85.1%	100.0%
Total		Count	17	102	119
		% within pseudomonas_gabung	14.3%	85.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)

Pearson Chi-Square	.870[a]	1	.351		
Continuity Correction[b]	.078	1	.780		
Likelihood Ratio	1.578	1	.209		
Fisher's Exact Test				1.000	.456
Linear-by-Linear Association	.863	1	.353		
N of Valid Cases	119				

a. 2 cells (50,0%) have expected count less than 5. The minimum expected count is ,71.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
For cohort histopatologikanker = non kanker	1.175	1.088	1.269
N of Valid Cases	119		